# TRx0237 for the Treatment of Early and Mild-Moderate Alzheimer's Disease

> **NCT03539380** · — · AVAILABLE · sponsor: **TauRx Therapeutics Ltd**

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** TRx0237

## Key facts

- **NCT ID:** NCT03539380
- **Lead sponsor:** TauRx Therapeutics Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2024-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03539380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03539380, "TRx0237 for the Treatment of Early and Mild-Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03539380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*